Lantheus/$LNTH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lantheus
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
Ticker
$LNTH
Sector
Primary listing
Employees
1,193
Headquarters
Website
Lantheus Metrics
BasicAdvanced
$5.5B
24.61
$3.41
-0.14
-
Price and volume
Market cap
$5.5B
Beta
-0.14
52-week high
$108.91
52-week low
$47.25
Average daily volume
993K
Financial strength
Current ratio
2.699
Quick ratio
2.199
Long term debt to equity
56.771
Total debt to equity
57.188
Interest coverage (TTM)
15.81%
Profitability
EBITDA (TTM)
382.309
Gross margin (TTM)
61.10%
Net profit margin (TTM)
15.15%
Operating margin (TTM)
20.25%
Effective tax rate (TTM)
25.57%
Revenue per employee (TTM)
$1,290,000
Management effectiveness
Return on assets (TTM)
9.27%
Return on equity (TTM)
21.45%
Valuation
Price to earnings (TTM)
24.61
Price to revenue (TTM)
3.674
Price to book
4.97
Price to tangible book (TTM)
42.51
Price to free cash flow (TTM)
16.245
Free cash flow yield (TTM)
6.16%
Free cash flow per share (TTM)
5.166
Growth
Revenue change (TTM)
0.50%
Earnings per share change (TTM)
-21.79%
3-year revenue growth (CAGR)
18.13%
10-year revenue growth (CAGR)
18.04%
3-year earnings per share growth (CAGR)
104.28%
10-year earnings per share growth (CAGR)
18.91%
What the Analysts think about Lantheus
Analyst ratings (Buy, Hold, Sell) for Lantheus stock.
Lantheus Financial Performance
Revenues and expenses
Lantheus Earnings Performance
Company profitability
Lantheus News
AllArticlesVideos
Lantheus Holdings Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lantheus Holdings, Inc. - LNTH
Business Wire·2 months ago
Lantheus Holdings Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lantheus Holdings, Inc. - LNTH
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lantheus stock?
Lantheus (LNTH) has a market cap of $5.5B as of April 17, 2026.
What is the P/E ratio for Lantheus stock?
The price to earnings (P/E) ratio for Lantheus (LNTH) stock is 24.61 as of April 17, 2026.
Does Lantheus stock pay dividends?
No, Lantheus (LNTH) stock does not pay dividends to its shareholders as of April 17, 2026.
When is the next Lantheus dividend payment date?
Lantheus (LNTH) stock does not pay dividends to its shareholders.
What is the beta indicator for Lantheus?
Lantheus (LNTH) has a beta rating of -0.14. This means that it has an inverse relation to market volatility.